Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesReShape Lifesciences Inc

ReShape Lifesciences Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-08-28T20:12:08.189619Z
Market Cap
4.87M

Momentum Score

…

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.14
Low
2.58
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
15.68
Dividend Yield
-
Revenue TTM
8.34M
Revenue Per Share
0.73
Gross Profit TTM
6.80M
Debt / Equity
0.04
ROE
-177.64%
Net Debt
-4.30M
ROCE
-389.61%
Diluted EPS TTM
-0.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -46.59M -62.04M -21.81M -75.10M -38.71M
Net income -46.21M -61.93M -21.63M -74.21M -81.15M
Selling general administrative 17.25M 24.41M 10.53M 17.22M 19.26M
Selling and marketing expenses 14.09M 9.16M 4.69M 4.85M -
Gross profit 6.80M 8.35M 6.26M 9.30M 0.44M
Reconciled depreciation 2.15M 1.97M 1.67M 1.71M 0.44M
Ebit -27.08M -29.72M -14.12M -15.89M -24.55M
Ebitda -24.91M -27.75M -12.46M -17.22M -24.11M
Depreciation and amortization 2.16M 1.97M 1.67M -1.34M 0.44M
Non operating income net other - - -7.30M -1.16M -0.16M
Operating income -27.08M -27.75M -12.46M -15.89M -38.55M
Other operating expenses 38.32M 41.35M 23.76M 30.98M 25.15M
Interest expense 0.11M 0.83M 2.05M 0.45M 0.01M
Tax provision -0.38M -0.11M -0.18M -0.89M -3.45M
Net interest income -0.11M -0.83M -2.05M -0.45M -0.01M
Non recurring - - - 8.09M 14.00M
Income tax expense -0.38M -0.11M -0.18M -0.89M -3.45M
Total revenue 11.24M 13.60M 11.30M 15.09M 0.61M
Total operating expenses 33.88M 36.10M 18.72M 25.19M 24.98M
Cost of revenue 4.44M 5.25M 5.04M 5.78M 0.16M
Total other income expense net -19.52M -34.29M -9.35M -59.21M -14.16M
Discontinued operations - - - - -45.88M
Net income from continuing ops -46.21M -61.93M -21.63M -74.21M -35.27M
Net income applicable to common shares -46.21M -61.93M -21.63M -74.21M -84.23M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 10.73M 11.14M 54.26M 37.06M 39.66M
Intangible assets - 0.26M 20.83M 27.02M 28.67M
Other current assets 0.34M 0.08M 1.62M 1.07M 1.71M
Total liab 4.06M 7.48M 8.19M 22.57M 15.55M
Total stockholder equity 6.66M 3.66M 46.07M 14.49M 24.11M
Deferred long term liab - - - 0.61M 0.70M
Other current liab 1.34M 4.87M 3.04M 7.24M 5.63M
Common stock 0.02M 0.00M 0.02M 0.01M 0.01M
Capital stock 0.02M 0.00M 0.02M 0.01M 0.00M
Retained earnings -635.57M -624.19M -576.76M -514.83M -493.20M
Other liab - - 0.85M 1.64M 4.68M
Other assets - 0.10M 1.46M 0.05M 0.10M
Cash 4.56M 3.85M 22.77M 2.96M 2.94M
Total current liabilities 3.78M 7.48M 7.33M 11.61M 10.39M
Current deferred revenue 0.64M 0.51M 0.55M 0.40M 0.20M
Net debt -4.30M -3.68M -22.49M -2.48M -2.17M
Short term debt 0.11M 0.17M 0.28M 0.31M 0.29M
Short long term debt total 0.26M 0.17M 0.28M 0.48M 0.77M
Other stockholder equity 642.30M 627.93M 622.91M 529.43M 517.30M
Property plant equipment - 0.87M 1.72M 0.58M 0.02M
Total current assets 10.30M 9.91M 30.25M 8.94M 10.11M
Net tangible assets - 3.40M 25.25M -12.54M -4.57M
Net receivables 1.66M 2.18M 2.81M 2.62M 4.10M
Long term debt - - - 9.17M 2.73M
Inventory 3.74M 3.61M 3.00M 2.24M 1.32M
Accounts payable 1.69M 1.93M 3.47M 3.65M 4.26M
Accumulated other comprehensive income -0.09M -0.09M -0.09M -0.12M -0.01M
Common stock total equity - - - 0.01M -
Preferred stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -514.83M -493.20M
Non currrent assets other 0.03M 0.05M 1.46M 0.05M 0.10M
Non current assets total 0.43M 1.23M 24.00M 28.12M 29.55M
Capital lease obligations 0.26M 0.17M 0.28M 0.48M 0.77M
Long term debt total - - - 9.17M 2.73M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.09M -0.09M 1.85M -2.39M -2.01M
Change to liabilities - 0.45M -1.48M -0.99M 1.63M
Total cashflows from investing activities - -0.09M 1.85M -2.39M -2.01M
Net borrowings - - -9.50M 10.40M -0.22M
Total cash from financing activities 17.57M 3.13M 33.30M 11.07M 13.66M
Change to operating activities - 0.77M -0.61M 0.96M 0.89M
Net income -11.39M -46.21M -61.93M -21.63M -74.21M
Change in cash 0.60M -18.86M 19.81M 0.02M -2.56M
Begin period cash flow 3.96M 22.82M 3.01M 2.98M 5.55M
End period cash flow 4.56M 3.96M 22.82M 3.01M 2.98M
Total cash from operating activities -16.96M -21.90M -15.38M -8.55M -14.20M
Issuance of capital stock - 0.64M 0.00M -14.61M 0.48M
Depreciation 0.15M 2.15M 1.97M 1.67M 1.71M
Other cashflows from investing activities - - - -2.00M -2.00M
Change to inventory -0.47M -1.19M -0.37M -1.18M -0.33M
Change to account receivables 0.12M 0.68M -0.28M 0.28M 0.58M
Sale purchase of stock - - - 0.68M 13.40M
Other cashflows from financing activities 17.57M 2.49M 40.99M 20.79M 13.66M
Change to netincome - 21.45M 46.83M 9.46M 57.84M
Capital expenditures 0.04M 0.13M 0.35M 0.39M 0.01M
Change receivables - - - 1.22M -3.62M
Cash flows other operating - - - 1.20M 2.34M
Cash and cash equivalents changes - - - 0.14M -2.56M
Change in working capital -4.13M 0.71M -2.74M 0.01M -1.43M
Stock based compensation 0.77M 2.09M 12.23M 1.32M 2.31M
Other non cash items -2.39M 19.79M 34.64M 10.17M 58.56M
Free cash flow -17.00M -22.03M -15.73M -8.94M -14.21M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ABT
Abbott Laboratories		 -0.71
0.65%		 108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.28
0.28%		 101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -2.16
0.68%		 316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 47.31 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

ReShape Lifesciences Inc

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

1001 Calle Amanecer, San Clemente, CA, United States, 92673

949 429 6680

https://www.reshapelifesciences.com

29

Name Title Year Born
Mr. Dan W. Gladney Exec. Chair 1953
Mr. Thomas Stankovich Sr. VP of Fin. & CFO 1961
Mr. Paul F. Hickey CEO, Pres & Director 1965
Dr. Mark B. Knudson Ph.D. Co-Founder and Special Advisor to the CEO 1949
Dr. Katherine S. Tweden Ph.D. Co-Founder 1961
Mr. Al Diaz VP of Operations and R&D NA
Dr. Dov Gal D.V.M., DVM, M.B.A., MBA VP of Regulatory Clinical Quality & Compliance Officer NA
Jody B. Dahlman Director of Communications NA
Mr. Naqeeb A. Ansari Sr. VP of Global Commercial Operations 1961
Mr. Dan W. Gladney Executive Chair 1953

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…